Project Aura: Co-design of a Home-based Monitoring Service

Anemia of Chronic Kidney Disease Clinical Trial

Official title:

Project Aura: Co-design of a Home-based Monitoring Service for Patients With Chronic Kidney Disease

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04112615
• Other study ID #: IRAS: 271364
• Status: Withdrawn
• Start date: February 17, 2020
• Est. completion date: June 15, 2020

Study information

• Verified date: February 2021
• Source: Entia Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Co-design of a home-based haemoglobin monitoring system with participants with anaemia of chronic kidney disease.

Description:

The device/monitoring system being developed measures the haemoglobin and haematocrit levels in blood from a single drop of blood. By measuring these blood parameter, participants are able to monitor their haemoglobin level at home.

The use of the device will take place in the participant's home to simulate what the investigators believe will be the ideal location for people who would prefer to self-manage their condition.

This study is a unique opportunity to gain feedback on the future design and development of a home-based monitoring system through user evaluation. As this is an adaptive/ iterative study design, this will give the Sponsor the opportunity to make changes to the user interface and user platform based on the feedback received from the end user.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 15, 2020
• Est. primary completion date: June 15, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion criteria:

For patients:

• Adequate English to participate in focus groups without an interpreter

• Patients of the study site who are currently undergoing treatment for anaemia of CKD

• Patients willing to participate in at least one or more 60-minute and ideally 90-minute focus groups at the designated study location, time and date.

• Patients capable of providing informed consent before attending the first focus group

For carers:

• Should be the primary carer nominated by a patient who fulfils the inclusion criteria, this includes parents of affected children

• Should be willing to participate in at least 60-minute and ideally 90-minute focus groups at the designated study location, time and date.

• Carers can only participate in the study with the patient he/she is caring for. The patient has also to be involved in the study

• Carers need to be capable of providing informed consent before attending the first focus group

For healthcare professionals:

• All clinicians need to be current employees of the study site

• Doctors need to be employed at Specialist Registrar, Fellow or Consultant Level

• Nurses of all grades are invited to participate but ideally need to have had some involvement in the outpatient care of CKD patients with anaemia

All participants:

• Should be willing to have the session's recorded audio, transcripts and analysed data from the focus groups shared with Entia.

• should be willing to attend multiple 60 to 90 minute focus groups.

• should be willing for unidentifiable photos and video footage to be taken during the interview.

• Participants attending focus groups later in the development process must be comfortable consenting to finger prick testing/ assessing the ease of use of the test disposable

Exclusion criteria:

Patients:

• Does not have adequate English to participate in focus group interviews without an interpreter.

• Patients of the study site who are not currently undergoing treatment or have previously undergone treatment within the past 12 months.

• Patients not willing to participate in at least 60-minute and ideally 90-minute focus group discussion at the designated study location, time and date.

• Participant not capable of providing consent or have a suitable, legally acceptable representative present to provide consent before the focus group interview.

For carers:

• Is not the nominated primary carer of a patient who fulfils the inclusion criteria, this includes parents of affected children

• Not paired with a patient that is involved in the study

• Carers not willing to participate in at least a 60-minute and ideally 90-minute focus group discussion at the designated study location, time and date.

For healthcare professionals:

None.

Related Conditions & MeSH terms

• Anemia of Chronic Kidney Disease
• Kidney Diseases
• Renal Insufficiency, Chronic

Intervention

Device:
• Blood measurement
Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.

Locations

Country	Name	City	State
United Kingdom	Hull University Teaching Hospitals NHS Trust	Hull

Sponsors (1)

Lead Sponsor	Collaborator
Entia Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Qualitative capture of user feedback- focus groups	User feedback gathered from participants using the blood measurement device will be used to inform the changes necessary to develop a successful home-based haemoglobin monitoring system.; Feedback will be analysed based on framework analysis.	12 months